Marshall Wace LLP Buys 152,191 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Marshall Wace LLP raised its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 641.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 175,913 shares of the company’s stock after acquiring an additional 152,191 shares during the period. Marshall Wace LLP owned approximately 0.37% of Mirum Pharmaceuticals worth $7,274,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Barclays PLC boosted its stake in shares of Mirum Pharmaceuticals by 4.6% during the 3rd quarter. Barclays PLC now owns 245,918 shares of the company’s stock worth $9,592,000 after purchasing an additional 10,824 shares during the period. Geode Capital Management LLC boosted its position in shares of Mirum Pharmaceuticals by 3.2% during the third quarter. Geode Capital Management LLC now owns 936,197 shares of the company’s stock valued at $36,519,000 after buying an additional 29,017 shares during the period. Lord Abbett & CO. LLC bought a new position in shares of Mirum Pharmaceuticals during the third quarter valued at approximately $28,913,000. Hennion & Walsh Asset Management Inc. grew its stake in shares of Mirum Pharmaceuticals by 25.5% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 145,599 shares of the company’s stock valued at $6,021,000 after buying an additional 29,545 shares during the last quarter. Finally, Avanza Fonder AB purchased a new stake in shares of Mirum Pharmaceuticals in the fourth quarter worth approximately $189,000.

Mirum Pharmaceuticals Stock Performance

MIRM stock opened at $39.43 on Wednesday. Mirum Pharmaceuticals, Inc. has a 1-year low of $23.14 and a 1-year high of $54.23. The business has a 50-day moving average price of $44.76 and a 200 day moving average price of $43.97. The company has a market capitalization of $1.95 billion, a P/E ratio of -19.52 and a beta of 1.00. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The business had revenue of $99.41 million during the quarter, compared to the consensus estimate of $96.64 million. As a group, equities research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Insider Buying and Selling

In other news, COO Peter Radovich sold 2,627 shares of the firm’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $48.22, for a total value of $126,673.94. Following the sale, the chief operating officer now directly owns 26,961 shares in the company, valued at approximately $1,300,059.42. This trade represents a 8.88 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Christopher Peetz sold 6,837 shares of the business’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $47.92, for a total transaction of $327,629.04. Following the transaction, the chief executive officer now owns 125,022 shares of the company’s stock, valued at approximately $5,991,054.24. This trade represents a 5.19 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 116,473 shares of company stock valued at $5,249,134 over the last 90 days. Corporate insiders own 22.87% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Robert W. Baird upped their price objective on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a research report on Thursday, February 27th. HC Wainwright upped their price target on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $58.20.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.